Who founded Nitrase Therapeutics?

Nitrase Therapeutics was founded by Irene Griswold-Prenner in 2018.

Who are Nitrase Therapeutics's investors?

Nitrase Therapeutics's investors include Mission Biocapital, Sofinnova Partners, Dementia Discovery Fund, Mission Bay Capital.

Nitrase Therapeutics

Founded 2018 · 14 employees on LinkedIn · 4 known investors

Find your way into Nitrase Therapeutics

128 people in our graph share verified history with the Nitrase Therapeutics team — schools, employers, funds. One of them is your warm intro.

Sam Blackmanunlockedknows Irene Griswold-Prenner · together at University of Chicago (overlapped)

knows the team · via Nitrase Therapeutics

×6knows the team · via University of Chicago

×2knows the team · via University of Colorado Boulder

×2knows the team · via Elan Pharmaceuticals

Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration. Its lead program is an antibody targeting the pathogenic form of alpha-synuclein in Parkinson's disease, with a pipeline aimed at neurodegenerative, cancer, fibrotic, respiratory, and autoimmune diseases.

Biotech Healthtech Longevity

Founders & leadership

Nitrase Therapeutics was founded in 2018 by Irene Griswold-Prenner.

Irene Griswold-Prenner inFounder & Chief Executive OfficerGriswold-Prenner holds a PhD in Drug Target and Discovery from the University of Chicago and has prior experience in biotechnology, stem cell research, and neuroscience drug development. She is Founder and CEO of Nitrase Therapeutics, a clinical-stage biopharmaceutical company developing therapeutics based on nitrases for neurodegenerative and other diseases.

Investors · 4

Mission BiocapitalSan Francisco · $500K

Sofinnova PartnersParis · $540K – $27M

Dementia Discovery FundreportedLondon

Mission Bay CapitalreportedSan Francisco

Competitors · 5

by search overlap

Bioworld5 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Integrated Nanotherapeutics Inc.4 shared keywordsIntegrated Nanotherapeutics develops lipid nanoparticle science and drug formulations for therapeutic applications. The company is led by scientists with over 100 years of collective expertise in preclinical research and drug development.

Nurix Therapeutics4 shared keywordsNurix Therapeutics develops protein degrader-based medicines using proprietary DEL-AI discovery technology to address cancer and autoimmune diseases. The company applies targeted protein degradation to overcome limitations of conventional therapeutic approaches.

Neutrolis3 shared keywordsNeutrolis is a clinical-stage biotech developing first-in-class therapies that degrade neutrophil extracellular traps (NETs) to address the root cause of autoimmune and inflammatory diseases such as lupus and rheumatoid arthritis. Its approach targets the process of NETosis to treat these disorders without relying on immunosuppression.

Doximity3 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.

Companies competing with Nitrase Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Nitrase Therapeutics Announces the Appointment of Three Industry Veterans to Its Board of Directors | The Manila Timesmanilatimes.net · Aug 2026

Team - Nitrase Therapeuticsnitrasetx.com · Oct 2021

Frequently asked questions

What does Nitrase Therapeutics do?: Nitrase Therapeutics is a clinical-stage biopharmaceutical company using its NITROME platform to develop therapeutics based on nitrases, a class of enzymes it discovered that drive protein nitration. Its lead program is an antibody targeting the pathogenic form of alpha-synuclein in Parkinson's disease, with a pipeline aimed at neurodegenerative, cancer, fibrotic, respiratory, and autoimmune diseases.
Who founded Nitrase Therapeutics?: Nitrase Therapeutics was founded by Irene Griswold-Prenner in 2018.
Who are Nitrase Therapeutics's investors?: Nitrase Therapeutics's investors include Mission Biocapital, Sofinnova Partners, Dementia Discovery Fund, Mission Bay Capital.